A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443 NSC# 681239) and Sorafenib (BAY 43-9006 IND# 69896 NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to better diagnose leukemia.
Description
This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia.
Details
| Condition | Acute myeloid leukemia (AML) |
|---|---|
| Age | 29years or below |
| Clinical Study Identifier | TX1939 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.